Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	130
Overall Study	STARTED	Low Dose SPN-810 (18 mg)	65
Overall Study	STARTED	High Dose SPN-810 (36 mg)	138
Overall Study	Intent-to-Treat	Placebo	125
Overall Study	Intent-to-Treat	Low Dose SPN-810 (18 mg)	65
Overall Study	Intent-to-Treat	High Dose SPN-810 (36 mg)	135
Overall Study	Safety	Placebo	126
Overall Study	Safety	Low Dose SPN-810 (18 mg)	65
Overall Study	Safety	High Dose SPN-810 (36 mg)	137
Overall Study	COMPLETED	Placebo	114
Overall Study	COMPLETED	Low Dose SPN-810 (18 mg)	58
Overall Study	COMPLETED	High Dose SPN-810 (36 mg)	101
Overall Study	NOT COMPLETED	Placebo	16
Overall Study	NOT COMPLETED	Low Dose SPN-810 (18 mg)	7
Overall Study	NOT COMPLETED	High Dose SPN-810 (36 mg)	37

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02618408/flow